Copyright © 2010 IUPHAR
Annotated and expert reviewed. Please contact us if you can help with updates.
5-HT2A
Previous and Unofficial Names  |
| 'D' receptor |
Structural Information  |
|
class A G protein-coupled receptor |
| Species |
TM |
AA |
Chromosomal Location |
Gene Name |
Reference |
| Human |
7 |
471 |
13q14-q21 |
HTR2A
|
4 |
| Rat |
7 |
471 |
15q11 |
Htr2a
|
161 |
| Mouse |
7 |
471 |
14 D2 |
Htr2a
|
162-163 |
|
|
Database Links  |
|
ChEMBL Target |
107 (Hs), 10620 (Mm), 12687 (Rn) |
|
Ensembl |
ENSG00000102468 (Hs), ENSMUSG00000034997 (Mm), ENSRNOG00000010063 (Rn) |
|
Entrez Gene |
3356 (Hs), 15558 (Mm), 29595 (Rn) |
|
GeneCards |
HTR2A (Hs) |
|
HomoloGene |
68073 (Hs) |
|
OMIM |
182135 (Hs) |
|
PharmGKB Gene |
PA193 (Hs) |
|
Protein Ontology (PRO) |
PRO:000001166 (Hs) |
|
RefSeq Nucleotide |
NM_000621 (Hs), NM_172812 (Mm), NM_017254 (Rn) |
|
RefSeq Protein |
NP_000612 (Hs), NP_766400 (Mm), NP_058950 (Rn) |
|
UniGene Hs. |
424980 (Hs) |
|
UniProt |
P28223 (Hs), P35363 (Mm), P14842 (Rn) |
|
Wikipedia |
5-HT2A |
| Search for 3D structures on the PDB |
|
Search using keywords: 5-Hydroxytryptamine receptors 5-HT2A
|
Search using accession numbers: P14842 || P28223 || P35363
|
| Agonists |
|
Key to terms and symbols
|
View all chemical structures |
Click column headers to sort
|
| Ligand |
|
|
|
|
|
[125I]DOI
|
|
|
|
|
Rn |
Full agonist |
9.1 |
pKd |
62 |
|
(+)-[3H]DOB
|
|
|
|
|
Hs |
Full agonist |
9.1 |
pKd |
183-184 |
|
5-HT
|
|
|
|
|
Hs |
Full agonist |
8.9 |
pKd |
184 |
|
ORG-5222
|
|
|
|
|
Hs |
Full agonist |
9.6 |
pKi |
65 |
|
LSD
|
|
|
|
|
Hs |
Full agonist |
9.4 |
pKi |
189 |
|
methylergonovine
|
|
|
|
|
Hs |
Full agonist |
9.4 |
pKi |
182 |
|
(R)-DOI
|
|
|
|
|
Hs |
Full agonist |
9.2 – 9.3 |
pKi |
182,185 |
|
(R)-DOI
|
|
|
|
|
Hs |
Full agonist |
9.2 |
pKi |
186 |
|
(+)-LSD
|
|
|
|
|
Hs |
Full agonist |
9.1 |
pKi |
182 |
|
DOB
|
|
|
|
|
Hs |
Full agonist |
8.9 – 9.2 |
pKi |
182,192 |
|
(+)-DOI
|
|
|
|
|
Hs |
Full agonist |
9.0 |
pKi |
182 |
|
ergotamine
|
|
|
|
|
Hs |
Partial agonist |
9.0 |
pKi |
182 |
|
S 16924
|
|
|
|
|
Hs |
Full agonist |
9.0 |
pKi |
66 |
|
5-MeOT
|
|
|
|
|
Hs |
Full agonist |
8.9 |
pKi |
188 |
|
AL-37350A
|
|
|
|
|
Hs |
Full agonist |
8.7 |
pKi |
186 |
|
lisuride
|
|
|
|
|
Hs |
Partial agonist |
8.6 |
pKi |
69 |
|
ergonovine
|
|
|
|
|
Rn |
Full agonist |
8.5 |
pKi |
188 |
|
LSD
|
|
|
|
|
Rn |
Full agonist |
8.5 |
pKi |
61 |
|
DOI
|
|
|
|
|
Hs |
Full agonist |
7.4 – 9.2 |
pKi |
184,187,192 |
|
terguride
|
|
|
|
|
Hs |
Partial agonist |
8.3 |
pKi |
69 |
|
cabergoline
|
|
|
|
|
Hs |
Full agonist |
8.2 |
pKi |
69 |
|
5-MeOT
|
|
|
|
|
Rn |
Full agonist |
8.1 |
pKi |
188 |
|
pergolide
|
|
|
|
|
Hs |
Full agonist |
8.1 |
pKi |
69 |
|
ergotamine
|
|
|
|
|
Rn |
Partial agonist |
8.0 |
pKi |
190 |
|
methylergonovine
|
|
|
|
|
Rn |
Full agonist |
7.9 |
pKi |
190 |
|
α-methyl-5-HT
|
|
|
|
|
Hs |
Full agonist |
7.8 |
pKi |
182 |
|
aripiprazole
|
|
|
|
|
Hs |
Full agonist |
7.5 – 8.1 |
pKi |
70,193 |
|
DOB
|
|
|
|
|
Rn |
Full agonist |
7.8 |
pKi |
191 |
|
GR-127935
|
|
|
|
|
Hs |
Full agonist |
7.8 |
pKi |
58,132 |
|
methysergide
|
|
|
|
|
Rn |
Partial agonist |
7.8 |
pKi |
190 |
|
aripiprazole
|
|
|
|
|
Rn |
Full agonist |
7.7 |
pKi |
70 |
|
org 12962
|
|
|
|
|
Hs |
Full agonist |
7.5 |
pKi |
182 |
|
org 37684
|
|
|
|
|
Hs |
Full agonist |
7.5 |
pKi |
182 |
|
TFMPP
|
|
|
|
|
Hs |
Full agonist |
7.5 |
pKi |
182 |
|
N-1-isopropyl-5-MeOT
|
|
|
|
|
Rn |
Full agonist |
7.4 |
pKi |
188 |
|
Ro 60-0175
|
|
|
|
|
Hs |
Full agonist |
7.4 |
pKi |
182 |
|
SB 216641
|
|
|
|
|
Hs |
Full agonist |
7.3 |
pKi |
58 |
|
5-HT
|
|
|
|
|
Hs |
Full agonist |
6.0 – 8.4 |
pKi |
182,184,186-189 |
|
BW723C86
|
|
|
|
|
Hs |
Full agonist |
7.2 |
pKi |
182 |
|
m-CPP
|
|
|
|
|
Hs |
Partial agonist |
6.8 – 7.5 |
pKi |
182,184,192 |
|
DOI
|
|
|
|
|
Rn |
Full agonist |
7.1 |
pKi |
181 |
|
N-1-isopropyltryptamine
|
|
|
|
|
Rn |
Full agonist |
7.1 |
pKi |
188 |
|
tryptamine
|
|
|
|
|
Rn |
Full agonist |
7.1 |
pKi |
188 |
|
bromocriptine
|
|
|
|
|
Hs |
Partial agonist |
7.0 |
pKi |
69 |
|
quetiapine
|
|
|
|
|
Hs |
Full agonist |
7.0 |
pKi |
65 |
|
quipazine
|
|
|
|
|
Hs |
Full agonist |
6.9 |
pKi |
182 |
|
RU 24969
|
|
|
|
|
Hs |
Full agonist |
6.9 |
pKi |
182 |
|
DOM
|
|
|
|
|
Rn |
Full agonist |
6.8 |
pKi |
191 |
|
donitriptan
|
|
|
|
|
Hs |
Full agonist |
6.7 |
pKi |
71 |
|
BRL-15572
|
|
|
|
|
Hs |
Full agonist |
6.6 |
pKi |
58 |
|
N-1-isopropyltryptamine
|
|
|
|
|
Hs |
Full agonist |
6.6 |
pKi |
188 |
|
tryptamine
|
|
|
|
|
Hs |
Full agonist |
5.5 – 7.6 |
pKi |
182,187-188 |
|
5-CT
|
|
|
|
|
Hs |
Full agonist |
6.5 |
pKi |
182 |
|
m-CPP
|
|
|
|
|
Rn |
Partial agonist |
6.4 |
pKi |
190 |
|
VER-3323
|
|
|
|
|
Hs |
Full agonist |
6.4 |
pKi |
182 |
|
N-1-isopropyl-5-MeOT
|
|
|
|
|
Hs |
Full agonist |
6.3 |
pKi |
188 |
|
5-HT
|
|
|
|
|
Rn |
Full agonist |
6.0 – 6.5 |
pKi |
181,190-191 |
|
MK-212
|
|
|
|
|
Hs |
Full agonist |
6.0 |
pKi |
182 |
|
α-methyl-5-HT
|
|
|
|
|
Rn |
Full agonist |
5.9 |
pKi |
181 |
|
SL65.0155
|
|
|
|
|
Hs |
Partial agonist |
5.9 |
pKi |
67 |
|
8-OH-DPAT
|
|
|
|
|
Hs |
Full agonist |
5.6 |
pKi |
182 |
|
CGS-12066
|
|
|
|
|
Hs |
Full agonist |
5.4 |
pKi |
182 |
|
LY344864
|
|
|
|
|
Hs |
Full agonist |
5.4 |
pKi |
64 |
|
quinpirole
|
|
|
|
|
Hs |
Full agonist |
5.0 – 5.5 |
pKi |
69,182 |
|
pindolol
|
|
|
|
|
Hs |
Full agonist |
5.0 |
pKi |
182 |
|
| View species-specific agonist tables |
| Antagonists |
|
Key to terms and symbols
|
View all chemical structures |
Click column headers to sort
|
| Ligand |
|
|
|
|
|
[3H]ketanserin
|
|
|
|
|
Hs |
Antagonist |
8.9 – 9.7 |
pKd |
184,189,202 |
|
[3H]-N-methylspiperone
|
|
|
|
|
Rn |
Antagonist |
9.1 |
pKd |
181 |
|
[3H]ketanserin
|
|
|
|
|
Rn |
Antagonist |
8.8 |
pKd |
181 |
|
AC-90179
|
|
|
|
|
Hs |
Inverse agonist |
9.7 |
pKi |
194 |
|
risperidone
|
|
|
|
|
Hs |
Inverse agonist |
9.3 – 10.0 |
pKi |
65,193,206 |
|
ritanserin
|
|
|
|
|
Hs |
Antagonist |
9.4 |
pKi |
197 |
|
sertindole
|
|
|
|
|
Hs |
Antagonist |
9.2 – 9.4 |
pKi |
65,193,206 |
|
LY86057
|
|
|
|
|
Hs |
Antagonist |
9.2 |
pKi |
188 |
|
ritanserin
|
|
|
|
|
Rn |
Antagonist |
9.2 |
pKi |
181,197 |
|
ziprasidone
|
|
|
|
|
Hs |
Antagonist |
8.8 – 9.5 |
pKi |
65,193,206 |
|
spiperone
|
|
|
|
|
Rn |
Antagonist |
9.0 – 9.2 |
pKi |
181,191 |
|
9-OH-risperidone
|
|
|
|
|
Hs |
Antagonist |
9.0 |
pKi |
65 |
|
amoxapine
|
|
|
|
|
Rn |
Antagonist |
9.0 |
pKi |
204 |
|
methysergide
|
|
|
|
|
Rn |
Antagonist |
8.4 – 9.5 |
pKi |
191,195 |
|
clozapine
|
|
|
|
|
Rn |
Inverse agonist |
8.9 |
pKi |
191 |
|
ketanserin
|
|
|
|
|
Hs |
Antagonist |
8.1 – 9.7 |
pKi |
55,182,184,196,202 |
|
cyamemazine
|
|
|
|
|
Hs |
Antagonist |
8.8 |
pKi |
55 |
|
ketanserin
|
|
|
|
|
Rn |
Antagonist |
8.6 – 9.0 |
pKi |
181,191 |
|
chlorpromazine
|
|
|
|
|
Rn |
Inverse agonist |
8.7 |
pKi |
191 |
|
mianserin
|
|
|
|
|
Rn |
Antagonist |
8.4 – 9.0 |
pKi |
191,204 |
|
mianserin
|
|
|
|
|
Hs |
Antagonist |
7.7 – 9.6 |
pKi |
54,182,195 |
|
olanzapine
|
|
|
|
|
Hs |
Antagonist |
8.6 – 8.7 |
pKi |
65,193,206 |
|
(+)-butaclamol
|
|
|
|
|
Hs |
Antagonist |
8.6 |
pKi |
187 |
|
mesulergine
|
|
|
|
|
Rn |
Antagonist |
8.6 |
pKi |
188 |
|
metergoline
|
|
|
|
|
Hs |
Antagonist |
8.6 |
pKi |
182 |
|
spiperone
|
|
|
|
|
Hs |
Antagonist |
7.8 – 9.4 |
pKi |
182,184,187 |
|
zotepine
|
|
|
|
|
Hs |
Antagonist |
8.6 |
pKi |
65 |
|
amesergide
|
|
|
|
|
Rn |
Antagonist |
8.5 |
pKi |
188 |
|
LY215840
|
|
|
|
|
Rn |
Antagonist |
8.5 |
pKi |
188 |
|
LY53857
|
|
|
|
|
Rn |
Antagonist |
8.5 |
pKi |
188 |
|
methiothepin
|
|
|
|
|
Hs |
Antagonist |
8.5 |
pKi |
182 |
|
risperidone
|
|
|
|
|
Rn |
Antagonist |
8.5 |
pKi |
191 |
|
sarpogrelate
|
|
|
|
|
Hs |
Antagonist |
8.5 |
pKi |
202 |
|
amitriptyline
|
|
|
|
|
Rn |
Antagonist |
8.4 |
pKi |
204 |
|
LY108742
|
|
|
|
|
Rn |
Antagonist |
8.4 |
pKi |
188 |
|
methysergide
|
|
|
|
|
Hs |
Antagonist |
8.4 |
pKi |
182 |
|
sergolexole
|
|
|
|
|
Rn |
Antagonist |
8.4 |
pKi |
188 |
|
clozapine
|
|
|
|
|
Hs |
Inverse agonist |
7.6 – 9.0 |
pKi |
65-66,182,193-194 |
|
pipamperone
|
|
|
|
|
Hs |
Antagonist |
8.3 |
pKi |
65 |
|
ritanserin
|
|
|
|
|
Hs |
Antagonist |
8.3 |
pKi |
182 |
|
perphenazine
|
|
|
|
|
Hs |
Antagonist |
8.2 |
pKi |
193 |
|
roxindole
|
|
|
|
|
Hs |
Antagonist |
8.2 |
pKi |
69 |
|
chlorpromazine
|
|
|
|
|
Hs |
Inverse agonist |
8.1 |
pKi |
193 |
|
loxapine
|
|
|
|
|
Hs |
Inverse agonist |
8.1 |
pKi |
193 |
|
amesergide
|
|
|
|
|
Hs |
Antagonist |
8.0 |
pKi |
188 |
|
fluspirilene
|
|
|
|
|
Hs |
Antagonist |
8.0 |
pKi |
65 |
|
trazodone
|
|
|
|
|
Rn |
Antagonist |
7.7 – 8.2 |
pKi |
190,204 |
|
LY215840
|
|
|
|
|
Hs |
Antagonist |
7.9 |
pKi |
188 |
|
trifluoperazine
|
|
|
|
|
Hs |
Antagonist |
7.9 |
pKi |
193 |
|
LY86057
|
|
|
|
|
Rn |
Antagonist |
7.8 |
pKi |
188 |
|
sergolexole
|
|
|
|
|
Hs |
Antagonist |
7.7 |
pKi |
188 |
|
thioridazine
|
|
|
|
|
Hs |
Antagonist |
7.4 – 8.0 |
pKi |
193,206 |
|
AMI-193
|
|
|
|
|
Hs |
Antagonist |
7.6 |
pKi |
182 |
|
LY53857
|
|
|
|
|
Hs |
Antagonist |
7.6 |
pKi |
188 |
|
MDL-11,939
|
|
|
|
|
Hs |
Antagonist |
7.6 |
pKi |
182 |
|
fluphenazine
|
|
|
|
|
Hs |
Antagonist |
7.5 |
pKi |
193 |
|
haloperidol
|
|
|
|
|
Rn |
Antagonist |
7.4 |
pKi |
191 |
|
trazodone
|
|
|
|
|
Hs |
Antagonist |
7.4 |
pKi |
182 |
|
pimozide
|
|
|
|
|
Hs |
Antagonist |
7.1 – 7.7 |
pKi |
193,206 |
|
thiothixene
|
|
|
|
|
Hs |
Antagonist |
7.3 |
pKi |
193 |
|
mesulergine
|
|
|
|
|
Hs |
Antagonist |
7.0 – 7.5 |
pKi |
182,184 |
|
LY314228
|
|
|
|
|
Hs |
Antagonist |
7.2 |
pKi |
196 |
|
haloperidol
|
|
|
|
|
Hs |
Antagonist |
6.7 – 7.3 |
pKi |
65-66,193-194 |
|
LY320954
|
|
|
|
|
Hs |
Antagonist |
7.0 |
pKi |
196 |
|
SB 228357
|
|
|
|
|
Hs |
Antagonist |
6.9 – 7.0 |
pKi |
197,200 |
|
apomorphine
|
|
|
|
|
Hs |
Antagonist |
6.9 |
pKi |
69 |
|
LY063518
|
|
|
|
|
Hs |
Antagonist |
6.9 |
pKi |
196 |
|
xanomeline
|
|
|
|
|
Hs |
Antagonist |
6.9 |
pKi |
73 |
|
bufotenine
|
|
|
|
|
Hs |
Antagonist |
6.8 |
pKi |
189 |
|
RS-102221
|
|
|
|
|
Rn |
Antagonist |
6.8 |
pKi |
198 |
|
SB 215505
|
|
|
|
|
Hs |
Antagonist |
6.8 |
pKi |
197 |
|
SB 243213
|
|
|
|
|
Hs |
Antagonist |
6.8 |
pKi |
200 |
|
quetiapine
|
|
|
|
|
Hs |
Antagonist |
6.4 – 7.0 |
pKi |
193,206 |
|
EGIS-7625
|
|
|
|
|
Rn |
Antagonist |
6.5 |
pKi |
195 |
|
fluoxetine
|
|
|
|
|
Rn |
Antagonist |
6.5 |
pKi |
190 |
|
L-741,626
|
|
|
|
|
Hs |
Antagonist |
6.5 |
pKi |
75 |
|
molindone
|
|
|
|
|
Hs |
Antagonist |
6.5 |
pKi |
193 |
|
SB 242084
|
|
|
|
|
Hs |
Antagonist |
6.1 – 6.8 |
pKi |
182,201 |
|
duloxetine
|
|
|
|
|
Hs |
Antagonist |
6.3 |
pKi |
205 |
|
MPDT
|
|
|
|
|
Rn |
Antagonist |
6.3 |
pKi |
59 |
|
SB 221284
|
|
|
|
|
Hs |
Antagonist |
6.3 |
pKi |
182 |
|
SDZ SER-082
|
|
|
|
|
Hs |
Antagonist |
6.3 |
pKi |
182 |
|
EGIS-7625
|
|
|
|
|
Hs |
Antagonist |
6.2 |
pKi |
195 |
|
norfluoxetine
|
|
|
|
|
Rn |
Antagonist |
6.2 |
pKi |
190 |
|
RS-127445
|
|
|
|
|
Hs |
Antagonist |
6.0 |
pKi |
182 |
|
S33084
|
|
|
|
|
Hs |
Antagonist |
6.0 |
pKi |
75 |
|
RS-102221
|
|
|
|
|
Hs |
Antagonist |
5.5 – 6.0 |
pKi |
182,198 |
|
SB 206553
|
|
|
|
|
Hs |
Antagonist |
5.6 – 5.8 |
pKi |
182,199 |
|
agomelatine
|
|
|
|
|
Hs |
Antagonist |
5.4 |
pKi |
203 |
|
SB 224289
|
|
|
|
|
Hs |
Antagonist |
5.3 |
pKi |
182 |
|
pindolol
|
|
|
|
|
Hs |
Antagonist |
5.0 |
pKi |
182 |
|
MDL-100,907
|
|
|
|
|
Hs |
Antagonist |
6.5 – 9.3 |
pIC50 |
182-183,197 |
|
|
View species-specific antagonist tables
|
Primary Transduction Mechanisms
|
| Transducer |
Effector/Response |
|
|
Phospholipase C stimulation |
Secondary Transduction Mechanisms  |
| Transducer |
Effector/Response |
|
Gi/Go family |
Adenylate cyclase inhibition |
Tissue Distribution
|
| CNS: frontal cortex, piriform cortex, ventro-caudal part of CA3, medial mammillary nucleus, pontine nuclei and motor cranial nerve nuclei in the brainstem, and the ventral horn of the spinal cord. |
| Species: |
Rat |
| Technique: |
in situ hybridisation. |
| References: |
169 |
|
|
| CNS: striatum (nucleus accumbens, olfactory tubercle, and caudate putamen) |
| Species: |
Rat |
| Technique: |
in situ hybridisation. |
| References: |
170 |
|
|
| CNS: olfactory bulb, neocortex, claustrum, piriform cortex, mamillary bodies, pontine nuclei, red nucleus and cranial motor nuclei. |
| Species: |
Rat |
| Technique: |
Immunohistochemistry. |
| References: |
171 |
|
|
| Atrium, coronary artery > ventricle wall, epicardium. |
| Species: |
Human |
| Technique: |
RT-PCR. |
| References: |
29 |
|
|
| Sciatic nerve and Schwann cells. |
| Species: |
Rat |
| Technique: |
Immunohistochemistry. |
| References: |
172 |
|
|
| Lumbar dorsal root ganglia, superior cervical ganglia, lumbar sympathetic ganglia. |
| Species: |
Rat |
| Technique: |
RT-PCR. |
| References: |
33 |
|
|
| Renal artery. |
| Species: |
Rat |
| Technique: |
Western blotting and immunohistochemistry. |
| References: |
173 |
|
|
| Thymus, peripheral blood lymphocytes, spleen, mitogen-activated spleen cells. |
| Species: |
Rat |
| Technique: |
RT-PCR. |
| References: |
116 |
|
|
| CNS: parahippocampal gyrus and neocortical regions (superficial and middle laminae) > dentate gyrus, hippocampus (all fields), subiculum. |
| Species: |
Human |
| Technique: |
in situ hybridisation. |
| References: |
31 |
|
|
| Medulla oblongata and lamina IX of the spinal cord. |
| Species: |
Rat |
| Technique: |
in situ hybridisation. |
| References: |
174 |
|
|
| Spinal cord: dorsal horn. |
| Species: |
Human |
| Technique: |
Radioligand binding. |
| References: |
30 |
|
|
Functional Assays
|
| Measurement of IP3 levels in rat glomerular mesangial cells endogenously expressing the 5-HT2A receptor. |
| Species: |
Rat |
| Tissue: |
Glomerular mesangial cells. |
| Response measured: |
Increase in IP3 levels. |
| References: |
164 |
|
|
| Measurement of cAMP levels in rat glomerular mesangial cells endogenously expressing the 5-HT2A receptor. |
| Species: |
Rat |
| Tissue: |
Glomerular mesangial cells. |
| Response measured: |
Inhibition of cAMP accumulation. |
| References: |
164 |
|
|
| Measurement of IP levels (and cAMP levels) in AV12 cells transfected with the rat 5-HT2C receptor. |
| Species: |
Rat |
| Tissue: |
AV12 cells. |
| Response measured: |
Increase in IP levels (no change to cAMP). |
| References: |
167 |
|
|
| Measurement of intracellular Ca2+ levels using a fluorometric imaging plate reader (FLIPR) in CHO-K1 cells transfected with the human 5-HT2A receptor. |
| Species: |
Human |
| Tissue: |
CHO-K1 cells. |
| Response measured: |
Increase in intracellular [Ca2+]. |
| References: |
168 |
|
|
Physiological Functions
|
| Contraction. |
| Species: |
Human |
| Tissue: |
Coronary artery. |
| References: |
29 |
|
|
| Contraction. |
| Species: |
Rat |
| Tissue: |
Mesenteric artery. |
| References: |
175 |
|
|
| Contraction (via MAPK pathway). |
| Species: |
Rat |
| Tissue: |
Aorta. |
| References: |
176 |
|
|
| Enhancement of platelet activation induced by ADP and thrombin. |
| Species: |
Human |
| Tissue: |
Whole blood. |
| References: |
177 |
|
|
| Procoagulant and fibrinolyic activities. |
| Species: |
Rat |
| Tissue: |
Aortic endothelial cells. |
| References: |
178 |
|
|
| Potentiation of inflammatory pain in the periphery. |
| Species: |
Rat |
| Tissue: |
In vivo. |
| References: |
179-180 |
|
|
Physiological Consequences of Altering Gene Expression
|
| 5-HT2A receptor knockout mice exhibit a lack of contraction of colonic smooth muscle in response to 5-HT. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
166 |
|
|
To cite this receptor data page, please use the following:
Rodrigo Andrade, Nicholas M. Barnes, Gordon Baxter, Joel Bockaert, Theresa Branchek, Marlene L. Cohen, Aline Dumuis, Richard M. Eglen, Manfred Göthert, Mark Hamblin, Michel Hamon, Paul R. Hartig, René Hen, Katharine Herrick-Davis, Rebecca Hills, Daniel Hoyer, Patrick P. A. Humphrey, Klaus Peter Latté, Luc Maroteaux, Graeme R. Martin, Derek N. Middlemiss, Ewan Mylecharane, Stephen J. Peroutka, Pramod R. Saxena, Andrew Sleight, Carlos M. Villalon, Frank Yocca.
5-Hydroxytryptamine receptors: 5-HT2A. Last modified on 2010-06-28. Accessed on 2010-09-03. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=6.
Contact us | Print | Back to top | Help